Worldwide experiences and opinions of healthcare providers on eHealth for patients with interstitial lung diseases in the COVID-19 era
- Gizal Nakshbandi1,
- Catharina C. Moor1,
- Kerri A. Johannson2,
- Toby M. Maher3,
- Michael Kreuter4 and
- Marlies S. Wijsenbeek1⇑
- 1Department of Respiratory Medicine, Erasmus University Medical Centre, Rotterdam, Netherlands
- 2Department of Medicine, University of Calgary, Calgary, AB, Canada
- 3Keck School of Medicine of University of Southern California, Los Angeles, California, USA
- 4Center for Interstitial and Rare Lung Diseases, Thoraxklinik, University of Heidelberg, Germany and German Center for Lung Research, Heidelberg, Germany<CE: Please check the city name and country names is missing in ‘Center for Interstitial and Rare Lung Diseases, Thoraxklinik, University of Heidelberg’.>
- Marlies Wijsenbeek (m.wijsenbeek-lourens{at}erasmusmc.nl)
Footnotes
This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.
Conflict of interest: Dr. Nakshbandi has nothing to disclose.
Conflict of interest: Dr. Moor reports grants and other from Boehringer-Ingelheim, outside the submitted work;.
Conflict of interest: Dr. Johannson reports grants, personal fees and other from Boehringer-Ingelheim, personal fees and other from Hoffman La Roche Ltd, personal fees and other from Theravance, personal fees and other from Blade Therapeutics, grants from Chest Foundation, grants from University of Calgary School of Medicine, grants from Pulmonary Fibrosis Society of Calgary, grants and personal fees from Three Lakes Foundation, personal fees from Pliant Therapeutic, outside the submitted work;
Conflict of interest: TMM has, via his institution, received industry-academic funding from Astra Zeneca and GlaxoSmithKline R&D and has received consultancy or speakers fees from Astra Zeneca, Bayer, Blade Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Galapagos, Galecto, GlaxoSmithKline R&D, IQVIA, Pliant, Respivant, Roche and Theravance.
Conflict of interest: Dr. Kreuter reports grants and personal fees from Boehringer Ingelheim, grants and personal fees from Roche, personal fees from Galapagos, outside the submitted work;.
Conflict of interest: Dr. Wijsenbeek reports grants and other from Boehringer-Ingelheim , grants and other from Hoffman la Roche, other from Galapagos , other from Respivant, other from Galecto, other from BMS, other from Novartis, other from Puretech, other from NeRRe therapeutics, outside the submitted work; . All grants and fees were paid to her institution.
This is a PDF-only article. Please click on the PDF link above to read it.
- Received June 18, 2021.
- Accepted June 21, 2021.
- Copyright ©The authors 2021
This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org